Patient characteristics at diagnosis grouped according to PCLI response
| Variables . | All patients . | PCLI response . | No PCLI response . | P . |
|---|---|---|---|---|
| Patients, n (%) | 176 | 94 (53) | 82 (47) | |
| Age, y, mean ± SD | 59 ± 10 | 59 ± 9 | 59 ± 10 | .81 |
| Sex, male, n (%) | 114 (64) | 53 (57) | 61 (74) | .025* |
| Baseline laboratory tests | ||||
| IgG/IgA/IgD/light chain, % | 57/25/2/15 | 32/14/1/6 | 25/11/1/8 | .16 |
| Kappa light chain, % | 64 | 54 | 69 | .039* |
| Hemoglobin, g/dL | 10.7 ± 2.0 | 10.7 ± 2.0 | 10.3 ± 2.0 | .32 |
| Serum creatinine, mg/dL | 1.6 ± 1.2 | 1.6 ± 1.1 | 1.6 ± 1.3 | .45 |
| β2 microglobulin, mg/dL | 5.6 ± 7.7 | 4.8 ± 4.1 | 6.5 ± 10.3 | .63 |
| Serum albumin, mg/dL | 3.6 ± 0.6 | 3.5 ± 0.5 | 3.7 ± 0.6 | .033* |
| ISS stage I/ II/ III, % | 32/44/24 | 24/48/28 | 38/41/21 | .14 |
| Initial PCLI, n (%) | ||||
| < 1% (low), | 60 (34) | 30 (32) | 30 (37) | .45 |
| ≥ 1 < 3% (intermediate) | 94 (53) | 50 (53) | 44 (54) | .72 |
| ≥ 3% (high) | 22 (13) | 15 (16) | 8 (10) | .15 |
| Initial serum M-spike, n = 146 | 3.6 ± 1.8 | 3.4 ± 1.7 | 3.8 ± 1.9 | .26 |
| No serum M spike | n = 30 | n = 14 | n = 16 | |
| Induction therapy, % | ||||
| Suboptimal | 71 | 68 | 74 | .41 |
| VAD | 14 | 12 | ||
| Dex | 10 | 11 | ||
| VBMCP | 10 | 6 | ||
| MP | 3 | 5 | ||
| DVD | 0 | 1 | ||
| Optimal | 29 | 32 | 26 | .41 |
| Thal-Dex | 10 | 7 | ||
| Rev-Dex | 5 | 4 | ||
| Vel-Dex | 1 | 0 | ||
| Stem cell transplantation after induction therapy, % | 68% | 72 | 64 | .31 |
| Variables . | All patients . | PCLI response . | No PCLI response . | P . |
|---|---|---|---|---|
| Patients, n (%) | 176 | 94 (53) | 82 (47) | |
| Age, y, mean ± SD | 59 ± 10 | 59 ± 9 | 59 ± 10 | .81 |
| Sex, male, n (%) | 114 (64) | 53 (57) | 61 (74) | .025* |
| Baseline laboratory tests | ||||
| IgG/IgA/IgD/light chain, % | 57/25/2/15 | 32/14/1/6 | 25/11/1/8 | .16 |
| Kappa light chain, % | 64 | 54 | 69 | .039* |
| Hemoglobin, g/dL | 10.7 ± 2.0 | 10.7 ± 2.0 | 10.3 ± 2.0 | .32 |
| Serum creatinine, mg/dL | 1.6 ± 1.2 | 1.6 ± 1.1 | 1.6 ± 1.3 | .45 |
| β2 microglobulin, mg/dL | 5.6 ± 7.7 | 4.8 ± 4.1 | 6.5 ± 10.3 | .63 |
| Serum albumin, mg/dL | 3.6 ± 0.6 | 3.5 ± 0.5 | 3.7 ± 0.6 | .033* |
| ISS stage I/ II/ III, % | 32/44/24 | 24/48/28 | 38/41/21 | .14 |
| Initial PCLI, n (%) | ||||
| < 1% (low), | 60 (34) | 30 (32) | 30 (37) | .45 |
| ≥ 1 < 3% (intermediate) | 94 (53) | 50 (53) | 44 (54) | .72 |
| ≥ 3% (high) | 22 (13) | 15 (16) | 8 (10) | .15 |
| Initial serum M-spike, n = 146 | 3.6 ± 1.8 | 3.4 ± 1.7 | 3.8 ± 1.9 | .26 |
| No serum M spike | n = 30 | n = 14 | n = 16 | |
| Induction therapy, % | ||||
| Suboptimal | 71 | 68 | 74 | .41 |
| VAD | 14 | 12 | ||
| Dex | 10 | 11 | ||
| VBMCP | 10 | 6 | ||
| MP | 3 | 5 | ||
| DVD | 0 | 1 | ||
| Optimal | 29 | 32 | 26 | .41 |
| Thal-Dex | 10 | 7 | ||
| Rev-Dex | 5 | 4 | ||
| Vel-Dex | 1 | 0 | ||
| Stem cell transplantation after induction therapy, % | 68% | 72 | 64 | .31 |
Cumulative percentages may not equal 100% because of rounding.
Dex indicates dexamethasone; DVD, doxorubicin, vincristine, dexamethasone; ISS, International Staging System; MP, melphalan, prednisone; PCLI, plasma cell labeling index; Rev-Dex, Revlimid (lenalidomide)-dexamethasone; Thal-Dex, thalidomide-dexamethasone; Vel-Dex, Velcade (bortezomib)-dexamethasone; VAD, vincristine, Adriamycin (doxorubicin), dexamethasone; and VBMCP, vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone.
Statistically significant.